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Abstract: Tapentadol is a centrally acting analgesic with a dual mechanism of action of mu 
receptor agonism and norepinephrine reuptake inhibition. Tapentadol immediate-release is 
approved by the US Food and Drug Administration for the management of moderate-  to-severe 
acute pain. It was developed to decrease the intolerability issue associated with opioids. 
  Tapentadol extended-release has a 12-hour duration of effect, and has recently been evaluated 
for pain in patients with chronic osteoarthritis, low back pain, and pain associated with diabetic 
peripheral neuropathy. Tapentadol extended-release was found to provide safe and highly 
effective analgesia for the treatment of chronic pain conditions, including moderate-to-severe 
chronic osteoarthritis pain and low back pain. Initial trials demonstrating efficacy in neuropathic 
pain suggest that tapentadol has comparable analgesic effectiveness and better gastrointestinal 
tolerability than opioid comparators, and demonstrates effectiveness in settings of inflammatory, 
somatic, and neuropathic pain. Gastrointestinal intolerance and central nervous system effects 
were the major adverse events noted. Tapentadol will need to be rigorously tested in chronic 
neuropathic pain, cancer-related pain, and cancer-related neuropathic pain.
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Background
Centrally acting analgesics with a dual mechanism of action have recently been 
developed in an attempt to reduce the tolerability issues associated with opioids while 
providing equivalent analgesia, and are being evaluated for the treatment of chronic 
pain. Tapentadol is a novel centrally acting analgesic, initially formulated as an 
immediate-release preparation. It is a potent Schedule II analgesic approved for use 
by the US Food and Drug Administration (FDA) in 2009, and is the first pain reliever 
developed in over 25 years for the management of moderate-to-severe acute pain.
Tapentadol immediate-release is available as 50, 75, and 100 mg tablets and provides 
4–6 hours of analgesia. Tapentadol immediate-release was shown to provide analgesia 
comparable with that of 10–15 mg of immediate-release oxycodone1,2 in patients 
recovering from dental extraction pain3 and pain following bunionectomy.4–6 It was 
also as effective as oxycodone in patients presenting with chronic osteoarthritis pain 
and chronic low back pain.7,8 Of importance in the comparator trials was the finding that 
patients treated with tapentadol had a lower incidence of adverse gastrointestinal events, 
including nausea, vomiting, and constipation, than those treated with oxycodone. In a 
bunionectomy trial, the composite incidence of nausea and vomiting in patients treated 
with tapentadol 50 mg every 6 hours was significantly lower than in patients treated with 
oxycodone 10 mg. Based on the safety and efficacy profile of the immediate-release Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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preparation, the Pricara division of Johnson and Johnson 
Pharmaceuticals made the decision to develop a preparation 
that provided a more prolonged duration of effect in an 
indication of chronic pain. The new preparation, tapentadol 
extended-release (ER), is a sustained-release tablet with a 
12-hour duration of effect for patients 18 years of age and older 
with moderate-to-severe chronic pain who require around the 
clock analgesic therapy.
At the time of writing, clinical development of tapentadol 
ER has been completed, submitted, and reviewed by the FDA. 
The submission included a number of large-scale, randomized, 
active comparator-controlled and placebo-  controlled Phase 
III studies that evaluated the safety and efficacy of tapent-
adol in patients with chronic osteoarthritis, low back pain, 
or pain associated with diabetic peripheral neuropathy. 
Tapentadol ER has also been evaluated in a 1-year, active-
controlled, open-label Phase III safety trial. The FDA has 
not requested additional efficacy trials, but in a complete 
response letter provided on November 2010, the agency 
seeks additional information regarding modifications to the 
ER tablet that increase mechanical resistance to   breaking or 
crushing prior to granting approval for use. In a series of large-
scale, controlled clinical trials, tapentadol ER was found to 
provide safe and highly effective analgesia for the treatment 
of chronic pain conditions, including moderate-to severe 
chronic osteoarthritis pain and lower back pain.1,2,4 Like the 
immediate-release preparation, it provides potent analgesia 
equivalent or superior to that of sustained-release opioids with 
an unexpected reduction in adverse gastrointestinal events. It 
also appears to have analgesic effectiveness comparable with 
that of opioid comparators, demonstrating effectiveness in 
settings of inflammatory, somatic, and neuropathic pain.
Pharmacology
Tapentadol produces potent analgesic effects via its 
dual mechanism of action, ie, mu receptor agonism and 
norepinephrine reuptake inhibition.9–12 In animal models, 
tapentadol behaves as a weak opioid agonist, with 50 times 
less affinity than morphine for the mu receptor. Despite 
this low binding affinity, tapentadol provides powerful 
analgesic effects, equivalent to one third that observed 
with equianalgesic doses of morphine.2,13 This finding and 
observations noted in Phase I human trials suggested that 
mu receptor activation provides a measurable but limited 
contribution to the analgesic effect of tapentadol.
Norepinephrine inhibits transmission of noxious 
impulses by activating alpha adrenergic receptors located 
on noxious nerve fibers in the spinal cord and central 
nervous system. Tapentadol has high selectivity for the 
norepinephrine transporter protein, and blocks reuptake 
of norepinephrine at the terminal endings of interneurons 
and descending inhibitory fibers. The resulting increase 
in norepinephrine further suppresses pain transmission at 
nociceptor endings. Unlike tramadol, which inhibits reuptake 
of both norepinephrine and serotonin, tapentadol has limited 
interaction with serotonin transporter proteins and minimal 
effect upon serotonin reuptake.1,2,13 Therefore, the risk of 
serotonin syndrome is less with tapentadol. Moreover, 
it was suggested that analgesia is more readily obtained 
by norepinephrine reuptake inhibition than by serotonin 
inhibition.14,15 From preliminary anecdotal information, it 
appears that treboxetine does not provide good analgesia. 
In addition, it has been seen that tricyclic antidepressants 
with more norepinephrine reuptake inhibition than serotonin 
reuptake inhibition do not appear to possess significantly 
more potent analgesic qualities than tricyclic antidepressants 
with more serotonin inhibition than norepinephrine reuptake 
inhibition.
Tapentadol exists as a single active enantiomer1,2,13 and 
is metabolized mainly by O-glucuronidation. Its principal 
metabolite is inactive, having no affinity for the mu receptor 
or the norepinephrine transporter. Because the analgesic 
activity of tapentadol is limited to the primary molecule, no 
enzymes are needed to convert it to an active metabolite, as 
is the case for tramadol and codeine. The development of 
tapentadol proceeded from the analgesic with a combined 
mechanism of action, ie, tramadol.16,17 Tramadol provides 
weak mu activation with inhibition of serotonin and 
norepinephrine uptake.18–20 The pharmacokinetic properties 
of tapentadol differ from those of tramadol in several ways. 
The parent molecule of tramadol inhibits the norepinephrine 
(-) enantiomer and serotonin reuptake (+) enantiomer, 
whereas the metabolite (O-desmethyl-metabolite) provides 
mu receptor activation.15,21 Therefore, any opioid-mediated 
analgesic activity of tramadol is dependent on the amount of 
metabolized fraction of parent drug. Tramadol is metabolized 
via the enzyme system cytochrome P450 (CYP) 2D6. 
Approximately 5%–15% of humans are so-called “poor 
metabolizers”, who do not experience satisfactory levels of 
analgesia with standard doses of tramadol. Unlike tramadol, 
the analgesic activity of tapentadol resides in the parent 
molecule, and, CYP2 D6 polymorphism plays no role in 
determining variations in analgesic response.22 This is very 
important because CYP enzymes contribute to clearance of Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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approximately two-thirds of the most commonly prescribed 
medications, including serotonin or norepinephrine reuptake 
inhibitors and mu receptor agonists.23,24 Tapentadol is 
metabolized predominantly by O-glucuronidation mediated 
by UGT1A9 and UGT2B7.25,26 The metabolites of tapentadol 
showed no analgesic activity in animal pain models,10 
and demonstrated no affinity for the mu receptor or the 
norepinephrine transporter in binding studies. Following oral 
administration of tapentadol, 99% of the parent molecule 
and its inactive conjugated metabolites which possess no 
appreciable analgesic activity are excreted via the kidneys. 
The manufacturer suggests that tapentadol should not be used 
in severe hepatic or renal failure. There have been no formal 
studies in these populations.24 The bioavailability of orally 
administered tapentadol is 32%, which is comparable with 
morphine, but less than methadone, tramadol, or oxycodone. 
With tapentadol given orally, the time taken to reach peak 
plasma concentration is 1.25–1.5 hours. The half-life is 
24 hours, and plasma protein binding is 20%.25
Extended-release preparation
The ER tapentadol preparation was specifically developed 
for the management of moderate-to-severe chronic pain. The 
controlled release formulation provides a 12-hour duration of 
activity, as well as the convenience and analgesic uniformity 
associated with twice per day dosing. The analgesic   efficacy 
of tapentadol is comparable with that of the classic ER 
  opioids, such as controlled-release oxycodone. Opioids have 
efficacy in inflammatory, somatic, and neuropathic pain 
conditions,42 as well as cancer pain. Based on several large-
scale clinical trials, described later in this paper, tapentadol 
ER is associated with better gastrointestinal tolerability, than 
the typical extended-duration opioids.
Mu receptor activation is a secondary mechanism 
responsible for the analgesic effect of tapentadol. Therefore, 
with chronic use, there is a relatively low degree of mu 
receptor activation as compared with potent mu opioids 
and, correspondingly, a slower onset of tolerance. One study 
demonstrated that the onset of tolerance with chronic use 
of tapentadol was significantly delayed as compared with 
morphine. With morphine treatment, the onset of tolerance 
was almost immediate, with complete tolerance by day 21. 
With tapentadol use, a progressive decline in efficiency was 
observed until day 18, followed by a plateau of moderate 
antinociception and complete tolerance on day 51.9,22 It 
is unclear whether benefits of reduced tolerance and dose 
escalation will be observed with long-term clinical use.
Clinical investigations
Osteoarthritis
A placebo and active-comparator controlled trial of tapentadol 
ER was performed in 670 patients with moderate-to-severe 
chronic pain related to chronic osteoarthritis of the knee.27,28 
Patients were randomly assigned to 28 days of treatment with 
tapentadol ER 100 mg or 200 mg, oxycodone controlled-
release 20 mg, or placebo twice daily. The primary endpoint 
was average pain intensity over the preceding 24 hours 
(100 mm on visual analog scale). Patients treated with tap-
entadol ER reported significantly reduced pain intensity vs 
placebo (-8.4 mm; P = 0.021), and   analgesia comparable 
with that in those treated with oxycodone controlled-release 
20 mg. More patients rated pain relief with tapentadol ER 
200 mg “very good” or “excellent” compared with placebo 
(48.8% vs 29.2%). Gastrointestinal disorders occurred in 
23% of placebo patients, 30% of patients treated with tap-
entadol ER 100 mg, 49% of patients treated with tapentadol 
ER 200 mg, and 56% of patients on oxycodone controlled-
release 20 mg. Constipation was much less common in the 
tapentadol ER 100 mg and 200 mg groups than in the oxy-
codone controlled-release group. Nervous system adverse 
events such as drowsiness, headache, and somnolence, 
were reported by 15%, 24%, 34%, and 43% of patients on 
placebo, tapentadol ER 100 mg, tapentadol ER 200 mg, and 
oxycodone controlled-release 20 mg, respectively.
Chronic low back pain
A large proportion of patients suffer from low back pain, with 
many having a predominant neuropathic pain component as 
well.29 The safety and effectiveness of tapentadol ER was 
evaluated in 958 patients presenting with chronic low back 
pain.13 In a randomized, controlled, blinded fashion, patients 
with moderate-to-severe pain were titrated over 3 weeks 
to achieve an effective and tolerable twice daily dose of 
tapentadol ER 100–250 mg, oxycodone HCl controlled 
release 20–50 mg, or placebo, and then maintained at that 
dose for 12 weeks.
Additional dose adjustments were allowed to maintain 
an optimal balance of efficacy and tolerability. Efficacy was 
measured as change in mean pain intensity from baseline 
to week 12. Two hundred and thirty-five patients in the 
tapentadol ER group and 199 patients in the oxycodone 
CR group entered the 12-week maintenance period. During 
this time interval, the average 24-hour dose for tapentadol 
ER was 400 mg, and for the oxycodone CR dose was 
80 mg. Patients treated with tapentadol ER benefited from Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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significantly greater reductions in average pain intensity 
than those on placebo. A higher percentage of patients 
completed treatment with tapentadol ER (54.1%) than with 
oxycodone CR (43.3%), mainly because of the lower rate of 
discontinuation due to gastrointestinal side effects (16.7% 
with tapentadol ER vs 32.3% with oxycodone CR). The 
authors concluded that tapentadol ER 100–250 mg twice 
daily relieved moderate-to-severe chronic low back pain 
more effectively than placebo, and with fewer adverse 
event-related discontinuations than oxycodone CR 20–50 mg 
twice daily.
Diabetic neuropathy pain
The effectiveness of tapentadol ER in managing moderate-
to-severe chronic pain was also evaluated in patients with 
diabetic peripheral neuropathy. This randomized, double-
blind trial involved diabetic patients aged 18 years or older 
with a diagnosis of moderate-to-severe painful diabetic 
peripheral neuropathy and symptoms for a minimum of 
6 months. During the 3-week, open-label period, 588 patients 
were titrated to an optimal dose of tapentadol ER 100–250 mg 
twice daily. The majority of these patients (79.4%) had a 
pain intensity rating $6 on an 11-point numeric rating scale. 
Patients were then advanced to the double-blind phase of the 
trial which consisted of a 12-week maintenance period, during 
which time patients continued on their study medication. A 
total of 395 patients who received tapentadol ER in the open-
label period and began the double-blind phase of treatment 
had a mean decrease in pain intensity from 7.3 indicating 
severe pain to 3.5 indicating mild pain during open-label 
treatment. During the double-blind period, the tapentadol ER 
group had an average pain intensity that remained relatively 
constant, while the placebo group had a pain intensity that 
increased in severity (P , 0.001).
During the open-label treatment phase, 20.1% of patients 
experienced the onset of one or more adverse events and 
discontinued the study. Following advancement to the 
double-blind phase, 11.2% of patients in the tapentadol ER 
group and 5.7% of patients in the placebo group discontinued 
due to adverse events. The most common adverse events 
were gastrointestinal and led to discontinuation in 10% of 
patients.30
The finding that tapentadol effectively suppressed 
neuropathic pain, while a mu receptor agonist was ineffective, 
may be related to the dual analgesic mechanism associated 
with this molecule. Agents that have a similar combined 
mechanism have been shown to be effective in the treatment 
of neuropathic pain conditions and, at the same time, are 
able to potentiate the opioid analgesics. Neuropathic pain 
is usually managed with tricyclic antidepressants, selective 
serotonin/norepinephrine reuptake inhibitors, anticonvulsants, 
antiarrhythmics, N-methyl-D-aspartate antagonists, and 
topical therapies. The antinociceptive, antiallodynic, 
and antihyperalgesic properties of tapentadol have been 
demonstrated in different rat models of acute and chronic 
pain. The models have included tail flick, hot plate, writhing, 
mustard oil colitis, chronic constriction injury, Randall 
Selitto test, and spinal nerve ligation.31,32 The efficacy of 
norepinephrine inhibitors, such as tricyclic and tetracyclic 
antidepressants, has been demonstrated in neuropathic pain 
models.14
Long-term safety in patients  
with chronic pain
The long-term safety and efficacy of tapentadol ER was 
evaluated in a large, randomized, open-label trial of patients 
with chronic pain.33 A total of 1117 patients were randomized 
in a 4:1 ratio to receive twice-daily doses of tapentadol ER 
50 mg or oxycodone CR 10 mg, which was increased over a 
3-day period to tapentadol 100 mg twice daily or oxycodone 
20 mg twice daily. Patients were maintained on these 
  analgesics for the next 51 weeks, although dose escalations 
or reductions were permitted. Additional breakthrough pain 
was treated with acetaminophen in both treatment groups. 
Over the 1-year study period, reductions in average pain 
intensity scores and total daily analgesic dose were stable 
in both groups.
Patients treated with tapentadol ER reported a lower 
overall incidence of treatment-related adverse gastrointestinal 
events, such as nausea, vomiting, and constipation. A lower 
proportion of patients treated with tapentadol ER experienced 
pruritus, but a greater number reported headache. Treatment-
related adverse events led to discontinuation in 22% of 
patients in the tapentadol ER group and in 36.8% of patients 
in the oxycodone CR group.2 Tapentadol ER has been shown 
to be effective for the management of moderate-to-severe 
chronic osteoarthritis-related knee pain. Despite the fact that 
oxycodone CR was shown to be a more potent medication 
than tapentadol ER with a 5:1 conversion rate (50 mg 
tapentadol ER to 10 mg oxycodone CR), a significantly 
higher proportion of patients in the tapentadol ER group 
(32%, P = 0.027) achieved more than 50% pain relief as 
compared with the oxycodone CR group (17.3%, P = 0.023).4 
In another study of more than 320 patients, both tapentadol 
ER and oxycodone CR provided at least a three-point drop 
on a 0–10 pain scale in patients with lower back pain.13Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Another study showed that the efficacy of tapentadol ER 
was comparable with that of oxycodone CR (P , 0.001).11 
Tapentadol ER was effective in the treatment of pain second-
ary to diabetic neuropathy, with 60.5% of patients reporting 
at least a 30% improvement in pain intensity and 34.8% at 
least a 50% improvement,43 as compared with data from 
three randomized, 15-week, double-blind, randomized, 
Phase III studies, ie, 39.7% and 27.0% in chronic low back 
pain patients,3 43% and 32% in patients with osteoarthritic 
knee pain,4 and 41.3% and 30.1% in those with lower back 
pain and osteoarthritic knee pain.11,16,34–39
Opioids have demonstrated analgesic effects comparable 
with those of tricyclics and gabapentin in the treatment of 
diabetic peripheral neuropathy. However, tolerability remains 
a significant issue limiting their use.37,40–46 Therefore,   opioids 
are considered a second-line treatment for neuropathic 
pain.30,47 Constipation affects an estimated 40%–95% of 
patients on long-term opioid therapy.36 Opioid-induced 
constipation rarely improves with time and can be difficult 
to manage with laxatives.48
Clinical studies with tapentadol ER showed that gastroin-
testinal side effects are of major importance. The incidence 
of nausea, vomiting, and constipation were 20.1%, 9.1%, 
and 13.8% in a 15-week study of tapentadol ER in low back 
pain,13 and 18.1%, 7.0%, and 22.6% in a 1-year study of 
patients with chronic low back pain and osteoarthritis pain,49 
and 21.4%, 8.0%, and 10.7% in patients with painful diabetic 
polyneuropathy.40
Benefits associated  
with tapentadol ER
In clinical trials, tapentadol ER has demonstrated an 
improved gastrointestinal tolerability profile compared with 
the comparator, oxycodone CR, at equianalgesic doses.5–8 
The incidence of adverse gastrointestinal effects was 43% 
in the tapentadol ER group and 67.3% in the oxycodone 
CR group.4 Tapentadol ER used for over 15 weeks provided 
relief for moderate-to-severe chronic low back pain and had 
a better gastrointestinal tolerability profile than oxycodone 
CR, with lower rates for nausea, vomiting, constipation, 
and pruritus.4,9,13 Another study demonstrated a lower 
incidence of nausea, vomiting, and constipation in the 
tapentadol ER group despite the fact the treatment duration 
was substantially longer (268 days with tapentadol ER vs 
59 days with oxycodone CR). In addition, the incidence 
of gastrointestinal effects leading to discontinuation of 
treatment was 2.5 times higher in the oxycodone group.49 
The observed lower incidence of adverse gastrointestinal 
effects is likely related to the dual synergistic mechanism 
of action of tapentadol ER, where appreciable levels of 
analgesia are achieved with a lesser degree of mu receptor 
activation.
The ability of tapentadol ER to suppress neuropathic 
as well as somatic pain suggests it will provide a broader 
spectrum of efficacy than the currently available ER 
analgesics. Opioid agonists have limited clinical effectiveness 
in the management of moderate-to-severe neuropathic pain 
and are not considered a first-line therapy,1,27,28,30 whereas 
analgesic medications with a combined mechanism of action, 
including norepinephrine reuptake inhibition, are effective 
against chronic pain.
Opioids are reserved for patients with refractory neu-
ropathic pain.28,33,50 In addition to that, the use of opioid 
  medications is limited because of the side effects   associated 
with mu receptor activation.14,51,52 This implies that the 
development of a compound combining both mechanisms 
of action is the way to improve the therapeutic range of 
opioids. Facilitation of monoaminergic transmission by 
blocking the reuptake of norepinephrine and/or serotonin in 
the descending pain inhibitory pathways53 of the spinal cord 
is efficacious in the treatment of chronic pain conditions and 
can enhance the analgesic effects of morphine.52
Adverse events
ER opioids, including tapentadol ER, are associated with a 
high incidence of side effects and treatment discontinuation. 
Major adverse effects reported in the Phase II and III tri-
als of tapentadol ER were gastrointestinal intolerance and 
central nervous system effects,1 including nausea, anxiety, 
diarrhea, and dizziness.40 A review of the literature shows 
that the   leading side effects of tapentadol are gastrointestinal, 
with nausea being the most common (30%), followed 
by vomiting (18%), somnolence (15%), and dizziness 
(24%). Significant changes in blood pressure have not been 
reported in the literature as a side effect of tapentadol ER. 
  Existing norepinephrine reuptake inhibition may potentially 
have cardiovascular effects, and more research in this 
area is necessary to determine if there are any significant 
cardiovascular effects. The literature on the tapentadol ER 
trials has not shown any vision-related side effects. Because 
tapentadol is a weak mu agonist, there is a potential for it to 
activate mu receptors in the Edinger-Westphal nucleus of the 
midbrain, resulting in a predominance of parasympathetic 
tone over sympathetic tone that, in turn, leads to myosis and 
accommodation. More research is warranted to determine if 
there are any significant effects on vision.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Contraindications
While not observed in controlled trials, tapentadol ER, 
like other extended-duration opioids, may be associated 
with significant respiratory depression, and should not be 
administered to patients with acute or severe bronchial 
asthma or hypercapnia in unmonitored settings or in 
the absence of resuscitative equipment. Tapentadol ER 
should also not be used by patients who are receiving 
monoamine oxidase inhibitors or who have taken them 
within the previous 14 days due to potential additive effects 
on norepinephrine levels which may result in adverse 
cardiovascular events.1,13 Tapentadol ER has the potential 
to precipitate serotonin syndrome and induce physical/
psychological dependence.9 Patients at risk of developing 
serotonin syndrome should not be treated with tapentadol. 
The development of a potentially life-threatening serotonin 
syndrome may occur with use of selective norepinephrine 
reuptake inhibitors, including tapentadol, particularly with 
concomitant use of serotonergic drugs, such as selective 
serotonin reuptake inhibitors, selective norepinephrine 
reuptake inhibitors, tricyclic antidepressants, monoamine 
oxidase inhibitors, and triptans, and drugs which impair 
metabolism of serotonin (including monoamine oxidase 
inhibitors). Serotonin syndrome may include changes in 
mental status (eg, agitation, hallucinations, and coma), 
autonomic instability (eg, tachycardia, labile blood pressure, 
and hyperthermia), and neuromuscular aberrations (eg, 
hyperreflexia and incoordination). Because tapentadol has 
effects on norepinephrine reuptake, patients may experience 
a monoamine syndrome of poorly characterized irritability 
and agitation, which resembles serotonin syndrome but is 
not associated with major complications.1,13
Tapentadol has an abuse potential similar to that of 
other potent opioid agonists and is subject to criminal 
diversion. It is unclear if the taper-resistant preparation will 
limit diversion, adulteration, and abuse. After 360 days 
of continuous administration, abrupt discontinuation of 
tapentadol was associated with mild to moderate withdrawal 
symptoms.
Based on tapentadol ER trials, dosing may range from 
100 mg from 200 mg twice daily, or higher. No dosage 
adjustment is needed in mild or moderate renal impairment. 
Tapentadol may be provided to opioid-dependent patients. 
Data taken from the 1-year safety trial, in which some 
patients had been taking opioids prior to enrollment, 
suggests that tapentadol doses of 200 mg or higher every 
12 hours may be appropriate.33 Both formulations of 
tapentadol, ie, immediate-release and ER, can be directly 
converted into equivalent or approximately equivalent total 
daily doses that provide comparable efficacy and safety. 
It is anticipated that tapentadol ER will be released as a 
Schedule II opioid analgesic. In an attempt to limit abuse, 
tapentadol ER will be formulated as a tamper-resistant tablet 
that cannot be easily adulterated. The tablet is designed to 
provide a high degree of mechanical resistance, such as 
crushing or chewing.4
Conclusion
Tapentadol ER is a novel analgesic with a combined mecha-
nism of action and clinical effectiveness comparable with 
that of commonly used medications. Based on preliminary 
clinical trials, tapentadol ER may offer an advance over 
standard controlled-release opioid preparations in that it 
offered improved gastrointestinal tolerability, less nausea 
and vomiting, and less constipation in the osteoarthritis and 
chronic low back pain efficacy trials than did oxycodone 
CR.28,30,33 It is unclear whether improvements in tolerability 
may reduce discontinuation of and greater patient compliance 
with therapy. Clearly, additional longer-term clinical trials 
are required to verify whether gastrointestinal side effects 
are lower with tapentadol than with the traditional opioids, 
such as morphine, hydromorphone, transdermal fentanyl, 
and methadone.
Initial trials demonstrating efficacy in neuropathic pain 
suggest that the dual analgesic effects of tapentadol may 
provide a broader analgesic spectrum than typical opioid 
analgesics. The pharmacokinetic profile of   tapentadol has a 
low potential for metabolic variation due to enzyme poly-
morphism, drug–drug interaction, and drug accumulation. 
Tapentadol has never been studied in patients with chronic 
liver or renal disease, or in those who are pregnant or   elderly.16 
Tapentadol will need to be rigorously tested in chronic 
neuropathic pain, cancer-related pain, and cancer-related 
neuropathic pain.
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